By using hepatocellular carcinoma (HCC) as a model, this study illustrates the role of SF3B4 as an oncogenic factor in HCC, highlighting its potential as a pan-cancer therapeutic target and diagnostic biomarker [228]. Here, SF3B4 is linked to hepatocellular carcinoma.